ORIC Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Updates
May 06, 2024 16:05 ET
|
ORIC Pharmaceuticals
Initiated three ORIC-114 Phase 1b expansion cohorts in NSCLC patients with EGFR exon 20 insertion, HER2 exon 20 insertion, or EGFR atypical mutations; updated Phase 1b data expected in the first half...
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
May 03, 2024 16:30 ET
|
ORIC Pharmaceuticals
SOUTH SAN FRANCISCO and SAN DIEGO, May 03, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address...
ORIC Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts in Phase 1b Trial of ORIC-114 in Patients with Mutated NSCLC
April 15, 2024 16:15 ET
|
ORIC Pharmaceuticals
Initiated multiple Phase 1b expansion cohorts to determine the RP2D of ORIC-114 in NSCLC patients with EGFR exon 20, HER2 exon 20, or EGFR atypical mutations Additionally, the company initiated an...
ORIC Pharmaceuticals Presents Preclinical Data on Two Programs at the 2024 American Association for Cancer Research (AACR) Annual Meeting
April 08, 2024 08:00 ET
|
ORIC Pharmaceuticals
ORIC-944, a potent and selective allosteric PRC2 inhibitor, demonstrates superior preclinical drug properties and longer clinical half-life which supports a potential best-in-class profile versus...
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
April 05, 2024 16:30 ET
|
ORIC Pharmaceuticals
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, April 05, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that...
ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences
April 04, 2024 16:30 ET
|
ORIC Pharmaceuticals
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, April 04, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that...
ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Updates
March 11, 2024 16:05 ET
|
ORIC Pharmaceuticals
Presented initial Phase 1b data from three clinical programs that support potential best in class profiles, with ORIC-944 and ORIC-114 prioritized for further advancement towards registrational...
ORIC Pharmaceuticals to Present at the Leerink Partners Global Biopharma Conference
March 06, 2024 16:30 ET
|
ORIC Pharmaceuticals
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, March 06, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that...
ORIC Pharmaceuticals Announces Multiple Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting
March 05, 2024 16:30 ET
|
ORIC Pharmaceuticals
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, March 05, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that...
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
March 01, 2024 16:30 ET
|
ORIC Pharmaceuticals
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, March 01, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that...